公开(公告)号：US20230414574A1

公开(公告)日：2023-12-28

申请号：US18061819

申请日：2022-12-05

申请人： SCIENTURE, INC.

发明人： Bhavya Teja KOLLA ,  Rahul SURANA ,  Suketu SANGHVI ,  Jigar BHATT

IPC分类号： A61K31/4178 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K31/4178 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

摘要： The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

公开(公告)号：US20230414521A1

公开(公告)日：2023-12-28

申请号：US18367416

申请日：2023-09-12

申请人： MURRAY AND POOLE ENTERPRISES LTD

发明人： Susanne Riel

IPC分类号： A61K9/20 ,  A61K47/26 ,  A61K47/36 ,  A61K47/02 ,  A61K47/38 ,  A61K47/12 ,  A61K45/06 ,  A61K31/165

CPC分类号： A61K9/2054 ,  A61K9/2018 ,  A61K9/2095 ,  A61K47/26 ,  A61K9/2059 ,  A61K47/36 ,  A61K47/02 ,  A61K9/2013 ,  A61K9/2009 ,  A61K47/38 ,  A61K47/12 ,  A61K45/06 ,  A61K31/165

摘要： Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.

公开(公告)号：US11850330B2

公开(公告)日：2023-12-26

申请号：US16349108

申请日：2017-11-10

申请人： Organovo, Inc.

发明人： Emily Bozek ,  Jonah Cool ,  Harry S. Rapoport ,  Christian Holmes ,  Stephen L. Pentoney ,  Chad Viergever ,  Howard Hwang ,  Christopher Shaw

IPC分类号： A61L27/60 ,  A61L27/38 ,  A61L27/52 ,  C12N5/071 ,  A61K35/36 ,  A61K47/36 ,  A61L27/24

CPC分类号： A61L27/60 ,  A61K35/36 ,  A61K47/36 ,  A61L27/3813 ,  A61L27/52 ,  C12N5/0626 ,  C12N5/0627 ,  C12N5/0629 ,  C12N5/0697 ,  A61L27/24 ,  C12N2533/74

摘要： Disclosed are compositions comprising cellular constructs comprising mesenchymal cells and epithelial cells. Also disclosed are methods of making the cellular constructs, methods of hair restoration, and kits. The invention also discloses parallel bio-printing systems and methods for making cellular constructs, such as cellular constructs comprising mesenchymal cells and epithelial cells.

公开(公告)号：US11850265B2

公开(公告)日：2023-12-26

申请号：US17033294

申请日：2020-09-25

申请人： RADIADERM LIMITED

发明人： Mark Lait ,  George Bishop

IPC分类号： A61K35/20 ,  A61K9/06 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/36 ,  A61K47/46 ,  A61K31/047 ,  A61K31/12 ,  A61K31/133 ,  A61K31/216 ,  A61K31/275 ,  A61K38/01

CPC分类号： A61K35/20 ,  A61K9/0009 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/047 ,  A61K31/12 ,  A61K31/133 ,  A61K31/216 ,  A61K31/275 ,  A61K38/018 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/36 ,  A61K47/46 ,  A61K31/047 ,  A61K2300/00 ,  A61K31/133 ,  A61K2300/00 ,  A61K31/275 ,  A61K2300/00 ,  A61K31/216 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00

摘要： The present invention relates to topical formulations comprising purified water, milk protein fluid and thickener, in particular a hydrogel and a lotion, and their use in treatment, in particular in a two-step process for the treatment of radiation dermatitis.

公开(公告)号：US20230398141A1

公开(公告)日：2023-12-14

申请号：US18024347

申请日：2021-09-08

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  MASSACHUSETTIS INSTITUTE OF TECHNOLOGY ,  BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

发明人： Carlo Giovanni Traverso ,  James D. Byme ,  Hannah Boyce ,  Leo E. Otterbein ,  David J. Gallo

IPC分类号： A61K33/00 ,  A61K9/12 ,  A61K45/06 ,  A61K47/36 ,  A61P1/04

CPC分类号： A61K33/00 ,  A61K9/122 ,  A61P1/04 ,  A61K47/36 ,  A61K45/06

摘要： A pharmaceutical composition is described that includes a pharmaceutical carrier comprising gas pockets containing carbon monoxide gas, wherein the pharmaceutical carrier is a foam, a solid, or a hydrogel. Methods of using the pharmaceutical composition to treat an inflammatory disease or condition, and methods of making the pharmaceutical composition, are also described.

公开(公告)号：US11839638B2

公开(公告)日：2023-12-12

申请号：US16303474

申请日：2017-05-22

申请人： Aboca S.p.A. Società Agricola

发明人： Valentino Mercati ,  Luisa Mattoli ,  Anna Maidecchi ,  Andrea Lugli

IPC分类号： A61K36/76 ,  A61K9/19 ,  A61K47/10 ,  A61K47/36

CPC分类号： A61K36/76 ,  A61K9/19 ,  A61K47/10 ,  A61K47/36 ,  A61K2236/333

摘要： The present invention relates to a composition comprising extract of poplar buds for use in the treatment of oropharyngeal cavity, urinary apparatus, digestive/excretory apparatus, skin affections and of bacterial infections.

公开(公告)号：US20230390210A1

公开(公告)日：2023-12-07

申请号：US18031669

申请日：2021-10-15

申请人： R.P. SCHERER TECHNOLOGIES, LLC

发明人： Karunakar Sukuru ,  Qi Fang

IPC分类号： A61K9/48 ,  A61K47/36

CPC分类号： A61K9/4866 ,  A61K9/4825 ,  A61K47/36

摘要： Described are modified release softgel capsules including a pH dependent shell composition that encapsulated a controlled release fill composition, methods of preparation thereof, and methods of use thereof. The pH dependent shell composition may be characterized in that the delayed release nature of the capsules may be achieved without a separate pH dependent coating or added conventional pH dependent polymers. The softgels provide a dual controlled release platform which facilitates delivery of the active agent to a target location in the gastrointestinal tract and a controlled release profile of the active agent at said target location in the gastrointestinal tract.

公开(公告)号：US11833244B2

公开(公告)日：2023-12-05

申请号：US17531658

申请日：2021-11-19

申请人： Gesea Biosciences Inc.

发明人： John H. Baillie ,  Ruth Baillie ,  George Blouin ,  Newsha Farahani ,  Christopher Marx

IPC分类号： A61K9/00 ,  A61K31/567 ,  A61K47/36 ,  A61K9/50 ,  A61F6/08 ,  A61F6/22 ,  A61K31/167 ,  A61K31/325 ,  A61K31/57 ,  A61K31/593 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61K47/28 ,  A61K31/192 ,  A61F2/30 ,  A61L27/54 ,  A61L27/58

CPC分类号： A61K9/0024 ,  A61F6/08 ,  A61F6/22 ,  A61K9/0002 ,  A61K9/5021 ,  A61K31/167 ,  A61K31/192 ,  A61K31/325 ,  A61K31/567 ,  A61K31/57 ,  A61K31/593 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61K47/28 ,  A61K47/36 ,  A61F2002/30677 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/404

摘要： A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.

公开(公告)号：US20230383037A1

公开(公告)日：2023-11-30

申请号：US18248565

申请日：2021-10-11

申请人： JOSHO GAKUEN EDUCATIONAL FOUNDATION ,  ADEKA CORPORATION

发明人： Shinji SAKUMA ,  Takumi TOMONO ,  Kohei MIYATA ,  Koichi SHIGENO

IPC分类号： C08F222/38 ,  A61K47/36 ,  A61K47/34

CPC分类号： C08F222/38 ,  A61K47/36 ,  A61K47/34

摘要： The object of the present invention is to provide an absorption enhancer capable of introducing high-molecular weight compounds into cells.
The object can be solved by a composition of the present invention comprising a polymer compound having a group represented by the following general formula (1) or the following general formula (2) at a side chain, and a compound to be administered with a molecular weight of 1,000 to 1,200,000.




wherein X1 is a residue of neutral amino acid or ω-aminoalkanoic acid in which an end amino group and an end carboxyl group are removed, X2 is a residue of cell-penetrating peptide in which an end amino group and an end carboxyl group are removed, X3 is a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms or a benzyloxy group, a is an integer of 0 to 50, and * denotes a bonding site.




wherein X4 is a residue of neutral amino acid or ω-aminoalkanoic acid in which an end amino group and an end carboxyl group are removed, X5 is a residue of cell-penetrating peptide in which an end amino group and an end carboxyl group are removed, X6 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a benzyl group, an acyl group having 1 to 6 carbon atoms, an arylsulfonyl group or an oxycarbonyl group, b is an integer of 0 to 50, and * denotes a bonding site.

公开(公告)号：US11826359B2

公开(公告)日：2023-11-28

申请号：US17061630

申请日：2020-10-02

申请人： Xeolas Pharmaceuticals Ltd.

发明人： Dennis Mark McDaid ,  Damien Patrick Flynn ,  Maurice Joseph Anthony Clancy

IPC分类号： A61K31/4439 ,  A61J1/00 ,  A61K9/00 ,  A61K47/36 ,  A61K47/02 ,  A61K47/14 ,  A61K47/26 ,  A61K9/16

CPC分类号： A61K31/4439 ,  A61J1/00 ,  A61K9/0053 ,  A61K9/1652 ,  A61K47/02 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36

摘要： The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.